<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01654263</url>
  </required_header>
  <id_info>
    <org_study_id>11-0034</org_study_id>
    <secondary_id>HHSN272201300018I</secondary_id>
    <nct_id>NCT01654263</nct_id>
  </id_info>
  <brief_title>A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine</brief_title>
  <official_title>A Phase IIb, Open-Label, Dose-Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed phase IIb randomized, open label, dose ranging, safety and immunogenicity study
      will evaluate two different doses of 13-valent pneumococcal conjugate vaccine (PCV13) in two
      groups of participants (55 through 74 years of age). First group vaccine na誰ve participants
      will be open-label to receive a single injection of 0.5 mL PCV13. Second group of participant
      previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23) will be
      randomized 1:1 to receive two injections of 0.5 mL PCV13, one dose in each arm (Group IIA or
      Group IIB). Blood samples will be obtained at baseline, at one month and six months
      post-vaccination. The primary objectives are: to determine if two 0.5 mL doses of PCV13 are
      statistically significantly more immunogenic than a single 0.5 mL dose of PCV13 for at least
      some of the vaccine serotypes among participants 55 through 74 years of age previously
      vaccinated with PPSV23, as measured by serotype-specific OPA titers 28 days after study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase IIb open-label immunogenicity and safety study to evaluate dosages of 0.5 mL
      and 1.0 mL (given as two 0.5 mL injections in separate arms) of PCV13 in adults 55 through 74
      years of age previously vaccinated with PPSV23. The study will enroll two groups of
      participants. Group I participants will all receive an open-label dose of 0.5 mL PCV13 and
      will include 294 adults 55-74 years of age who have not previously received 23-valent
      pneumococcal polysaccharide vaccine (PPSV23). Group II will be randomized 1:1 to receive 0.5
      mL PCV13 (Group IIA) or 0.5 mL PCV13 in the right arm and 0.5 mL PCV 13 in the left arm
      (Group IIB). Group II will include 588 adults 55 through 74 years of age who previously
      received a single dose of PPSV23 &gt; /=3 years and &lt; /=7 years prior to enrollment. Enrollment
      in both groups will be stratified by age group (55 through 64 years and 65 through 74
      years).The study duration is approximately 18 months. The primary objectives are: to
      determine if two 0.5 mL doses of PCV13 are statistically significantly more immunogenic than
      a single 0.5 mL dose of PCV13 for at least some of the vaccine serotypes among participants
      55 through 74 years of age previously vaccinated with PPSV23, as measured by
      serotype-specific OPA titers 28 days after study vaccination, and is non-inferior to 12
      vaccine serotypes; and determine if two 0.5 mL doses of PCV13 administered to participants
      previously vaccinated with PPSV23 are non-inferior to a single dose of 0.5 mL of PCV13
      administered to vaccine-na誰ve adults 55 through 74 years of age for the 12 vaccine serotypes,
      as measured by serotype-specific OPA titers 28 days after study vaccination. The secondary
      objectives of this study are to: determine if two x 0.5mL doses of PCV13 is statistically
      significantly more immunogenic than a single 0.5 mL dose of PCV13 for at least some of the
      vaccine serotypes among participants 55 through 74 years of age previously vaccinated with
      PPSV23, as measured by serotype-specific OPA titers 180 days after study vaccination, and is
      non-inferior to 12 vaccine serotypes; to determine if two x 0.5mL doses of PCV13 administered
      to participants previously vaccinated with PPSV23 is non-inferior to a single dose of 0.5 mL
      of PCV13 administered to vaccine-na誰ve adults 55 through 74 years of age for 12 vaccine
      serotypes, as measured by serotype-specific OPA titers 180 days after study vaccination.
      Parent protocol to sub-study 12-0031.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2012</start_date>
  <completion_date type="Actual">August 21, 2015</completion_date>
  <primary_completion_date type="Actual">August 21, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Local and Systemic Adverse Events</measure>
    <time_frame>Days 0 to Day 7 post vaccination</time_frame>
    <description>Participants maintained a memory aid to record daily the occurrence of local injection site reactions and systemic reactions for 8 days after vaccination based on their interference with daily activities for subjective symptoms or quantitative measurement of the reaction. All participants reporting events of any severity (mild, moderate, or severe) are counted. For measured reactions, participants are included if the reaction is &gt;0mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Unsolicited Vaccine-related Adverse Events.</measure>
    <time_frame>Up to Day 28 post vaccination</time_frame>
    <description>Association with PCV13 was determined by the investigator and defined as &quot;Related&quot;, meaning there was a known temporal relationship, or the event was known to occur in association with study product or with a product in a similar class of study products and no alternate etiology was identified.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Vaccine-related Serious Adverse Events.</measure>
    <time_frame>Up to Day 180 post vaccination</time_frame>
    <description>Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation thereof; was a congenital anomaly/birth defect; or may have jeopardized the participant, or required intervention to prevent one of the outcomes. Association with PCV13 was determined by the investigator and defined as &quot;Related&quot;, meaning there was a known temporal relationship, or the event was known to occur in association with study product or with a product in a similar class of study products and no alternate etiology was identified.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers of Serotype-specific Opsonophagocytic Antibody (OPA) to 12 Vaccine Serotypes at Days 0 and 28 Post Vaccination.</measure>
    <time_frame>Day 0 and Day 28 post vaccination</time_frame>
    <description>Blood was collected from all participants at Day 0 and Day 28 after receipt of vaccination. The geometric mean for each group was then assessed by serotype-specific opsonophagocytic antibody (OPA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Serotype-specific OPA Titer to 12 Vaccine Serotypes at Days 0 and 180 Post Vaccination.</measure>
    <time_frame>Day 0 and Day 180 post vaccination</time_frame>
    <description>Blood was collected from all participants at Days 0 and 180 after receipt of vaccination. The geometric mean for each group was then assessed by serotype-specific opsonophagocytic antibody (OPA).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">884</enrollment>
  <condition>Pneumococcal Infection</condition>
  <arm_group>
    <arm_group_label>Group IA: Pneumococcal vaccine-naive, age 55 - 64</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to 147 subjects vaccine-naive adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IB: Pneumococcal vaccine-naive, age 65 - 74</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open- label, PCV13 given as 0.5 mL IM injection to 147 subjects vaccine-naive adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IIA: age 55 - 64, previous PPSV23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IIAA: age 55 - 64, previous PPSV23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IIB: age 65 - 74, previous PPSV23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IIBB: age 65 - 74, previous PPSV23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]</intervention_name>
    <description>Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.</description>
    <arm_group_label>Group IA: Pneumococcal vaccine-naive, age 55 - 64</arm_group_label>
    <arm_group_label>Group IB: Pneumococcal vaccine-naive, age 65 - 74</arm_group_label>
    <arm_group_label>Group IIA: age 55 - 64, previous PPSV23</arm_group_label>
    <arm_group_label>Group IIAA: age 55 - 64, previous PPSV23</arm_group_label>
    <arm_group_label>Group IIB: age 65 - 74, previous PPSV23</arm_group_label>
    <arm_group_label>Group IIBB: age 65 - 74, previous PPSV23</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Male or female adults 55 through 74 years of age at the time of enrollment who are able
        to provide informed consent. 2. For the pneumococcal vaccine-na誰ve group (Group I), no
        pneumococcal vaccine received prior to enrollment, as documented by participant report and
        review of available vaccine records. For the previously vaccinated group (Group II),
        documented vaccination with exactly one dose of PPSV23 administered &gt;/=3 and &lt;/=7 years
        prior to enrollment and no other lifetime doses of PPSV23. (History of receipt or
        non-receipt of a pneumococcal vaccine may be presumptively ascertained by participant
        report but must be confirmed by review of primary source information, including but not
        limited to medical records, primary care or other provider report, and health department
        records. Medical records should be reviewed and/or primary care or other providers queried
        to identify pneumococcal vaccinations administered for a period of not less than 10 years
        prior to enrollment.) 3. Determined by medical history, targeted physical examination (if
        indicated), and clinical judgment to be eligible for the study. Subjects with preexisting
        stable disease, defined as disease not requiring significant change in therapy (A change in
        dose or therapy within a category (e.g., change from one nonsteroidal anti-inflammatory
        drug to another) is allowed. A change to a new therapy category (e.g. surgery or addition
        of a new pharmacological class) is only allowed if it is not caused by worsening disease.)
        or hospitalization for worsening disease 12 weeks prior to enrollment, are eligible. 4.
        Agree not to receive a live virus vaccine (for example, zoster vaccine) before the Day 28
        (Visit 03) blood specimen collection and not to receive an inactivated vaccine (for
        example, inactivated influenza vaccine) within 14 days after enrollment. 5. The subject is
        able to understand and comply with the planned study procedures including being available
        for all study visits. 6. The subject has provided informed consent prior to any study
        procedures.

        Exclusion Criteria:

        1. Receipt of any PCV or investigational pneumococcal vaccine prior to enrollment. 2.
        Receipt of any inactivated vaccine within 14 days prior to enrollment or receipt of any
        live vaccine within 30 days prior to enrollment. 3. Receipt of an allergy desensitization
        injection within 14 days prior to enrollment or planned receipt of an allergy
        desensitization injection within 7 days following enrollment. 4. Receipt of a diphtheria
        toxoid containing vaccine (for example, tetanus and diphtheria toxoid [Td] or tetanus and
        diphtheria toxoid and acellular pertussis [TdaP] vaccine) within six months prior to
        enrollment. 5. Known or suspected immunodeficiency, receipt of cancer chemotherapy or
        radiation therapy within the preceding 36 months, or receiving treatment with
        immunosuppressive therapy, including systemic corticosteroids, e.g., for cancer, HIV or
        autoimmune disease. If any systemic (oral, parenteral) corticosteroids have been
        administered for treatment of acute illness within 30 days of vaccination, and any long
        term use (&gt;2 weeks) in the 30 through 59 days before vaccination should be excluded.
        (Topical, intranasal, and inhaled corticosteroids are allowed.) 6. Serious chronic
        disorders including active or metastatic malignancy, hematologic malignancy, severe chronic
        obstructive pulmonary disease or clinically significant congestive heart failure,
        requirement for supplemental oxygen, end stage renal disease with or without dialysis,
        clinically unstable cardiac disease, or any other disorder that in the opinion of the
        investigator precludes the subject's participation. 7. Known HIV, hepatitis B or hepatitis
        C infection. 8. Residence in a nursing home or other skilled nursing facility or
        requirement for skilled nursing care. An ambulatory subject who does not require skilled
        nursing care and is a resident of a retirement home or community is eligible for the trial.
        9. Inability to provide informed consent or complete study activities, for example, due to
        dementia or other impairment. 10. Poor or missing eyesight, requiring third party support
        to read. 11. Receipt of any blood products, including immunoglobulin, within three months
        prior to enrollment. 12. Heart rate less than 40 bpm or greater than 120 bpm as measured at
        the enrollment visit and prior to vaccination. 13. Systolic blood pressure less than 90 mm
        Hg or greater than 170 mm Hg as measured at the enrollment visit and prior to vaccination.
        14. Diastolic blood pressure greater than 110 mm Hg as measured at the enrollment visit and
        prior to vaccination. 15. For Group I, unable to receive a vaccination in the deltoid
        muscle of the right arm and unable to receive a vaccination in the deltoid muscle of the
        left arm because of insufficient muscle mass, need to avoid injections due to prior lymph
        node dissection or radiation, or other factor. For Group II, unable to receive a
        vaccination in the deltoid muscle of one or both arms because of insufficient muscle mass,
        need to avoid injections due to prior lymph node dissection or radiation, or other factor.
        16. Currently on anticoagulant therapy (for example, warfarin, heparin [IV or SQ], or
        dabigatran) or a history of bleeding diathesis that would contraindicate intramuscular
        injection. (Aspirin, clopidogrel, dipyridamole, and nonsteroidal anti-inflammatory agents
        are allowed). 17. Known clinically significant allergic reaction to prior pneumococcal
        vaccination (for Group II participants) or to a component of PCV13 vaccine (PCV13 is latex
        free). 18. Current known abuse of alcohol or drug addiction that in the opinion of the
        Investigator may interfere with the subject's ability to comply with trial procedures. 19.
        Rec eipt of any other investigational vaccine or agent within one month before enrollment
        or intent to receive any other investigational vaccine or agent prior to the conclusion of
        the study. 20. Any medical condition that would, in the opinion of the investigator, place
        the participant at an unacceptable risk of an adverse event or interfere with the
        evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emory Vaccine Center - The Hope Clinic</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030-1705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa - Vaccine Research and Education Unit</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-2600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University - Center for Vaccine Development</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104-1015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center - Infectious Diseases</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Molecular Virology and Microbiology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Research Institute - Seattle - Vaccines and Infectious Diseases</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101-1466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 15, 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <results_first_submitted>August 11, 2016</results_first_submitted>
  <results_first_submitted_qc>November 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 23, 2017</results_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>13-valent</keyword>
  <keyword>23-valent</keyword>
  <keyword>elderly</keyword>
  <keyword>parent protocol</keyword>
  <keyword>Pneumococcal infections</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were healthy adult males and females, 55 through 74 years of age, recruited from existing volunteer populations and from the communities at large around the clinical sites. Participants were enrolled between 10OCT2012 and 03MAR2015.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>IA: Pneumococcal Vaccine-naive, Age 55-64, Single Injection</title>
          <description>Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to vaccine-naive adults ages 55-64.</description>
        </group>
        <group group_id="P2">
          <title>IB: Pneumococcal Vaccine-naive, Age 65-74, Single Injection</title>
          <description>Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to vaccine-naive adults ages 65-74.</description>
        </group>
        <group group_id="P3">
          <title>IIA: Age 55-64, Previous PPSV23, Single Injection</title>
          <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to adults ages 55-64 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
        </group>
        <group group_id="P4">
          <title>IIB: Age 65-74, Previous PPSV23, Single Injection</title>
          <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to adults ages 65-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
        </group>
        <group group_id="P5">
          <title>IIAA: Age 55-64, Previous PPSV23, Two Injections</title>
          <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to adults ages 55-64 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
        </group>
        <group group_id="P6">
          <title>IIBB: Age 65 - 74, Previous PPSV23, Two Injections</title>
          <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to adults ages 65-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="147"/>
                <participants group_id="P3" count="139"/>
                <participants group_id="P4" count="145"/>
                <participants group_id="P5" count="140"/>
                <participants group_id="P6" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="147"/>
                <participants group_id="P3" count="137"/>
                <participants group_id="P4" count="144"/>
                <participants group_id="P5" count="139"/>
                <participants group_id="P6" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants are included in the baseline analysis population.</population>
      <group_list>
        <group group_id="B1">
          <title>IA: Pneumococcal Vaccine-naive, Age 55-64, Single Injection</title>
          <description>Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to vaccine-naive adults ages 55-64.</description>
        </group>
        <group group_id="B2">
          <title>IB: Pneumococcal Vaccine-naive, Age 65-74, Single Injection</title>
          <description>Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to vaccine-naive adults ages 65-74.</description>
        </group>
        <group group_id="B3">
          <title>IIA: Age 55-64, Previous PPSV23, Single Injection</title>
          <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to adults ages 55-64 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
        </group>
        <group group_id="B4">
          <title>IIB: Age 65-74, Previous PPSV23, Single Injection</title>
          <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to adults ages 65-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
        </group>
        <group group_id="B5">
          <title>IIAA: Age 55-64, Previous PPSV23, Two Injections</title>
          <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to adults ages 55-64 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
        </group>
        <group group_id="B6">
          <title>IIBB: Age 65-74, Previous PPSV23, Two Injections</title>
          <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to adults ages 65-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="147"/>
            <count group_id="B3" value="139"/>
            <count group_id="B4" value="145"/>
            <count group_id="B5" value="140"/>
            <count group_id="B6" value="149"/>
            <count group_id="B7" value="884"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="139"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="140"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="443"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="145"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="149"/>
                    <measurement group_id="B7" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="2.8"/>
                    <measurement group_id="B2" value="67.6" spread="2.6"/>
                    <measurement group_id="B3" value="60.8" spread="2.7"/>
                    <measurement group_id="B4" value="70.5" spread="2.0"/>
                    <measurement group_id="B5" value="61.0" spread="2.8"/>
                    <measurement group_id="B6" value="70.3" spread="2.0"/>
                    <measurement group_id="B7" value="65.0" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="78"/>
                    <measurement group_id="B7" value="512"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="71"/>
                    <measurement group_id="B7" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="143"/>
                    <measurement group_id="B5" value="138"/>
                    <measurement group_id="B6" value="147"/>
                    <measurement group_id="B7" value="863"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="132"/>
                    <measurement group_id="B5" value="116"/>
                    <measurement group_id="B6" value="138"/>
                    <measurement group_id="B7" value="794"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="139"/>
                    <measurement group_id="B4" value="145"/>
                    <measurement group_id="B5" value="140"/>
                    <measurement group_id="B6" value="149"/>
                    <measurement group_id="B7" value="884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Local and Systemic Adverse Events</title>
        <description>Participants maintained a memory aid to record daily the occurrence of local injection site reactions and systemic reactions for 8 days after vaccination based on their interference with daily activities for subjective symptoms or quantitative measurement of the reaction. All participants reporting events of any severity (mild, moderate, or severe) are counted. For measured reactions, participants are included if the reaction is &gt;0mm.</description>
        <time_frame>Days 0 to Day 7 post vaccination</time_frame>
        <population>All participants who received vaccination are included. Data were analyzed regardless of age strata as pre-specified in the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group IA/B: Pneumococcal Vaccine-naive, Single Injection</title>
            <description>Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to vaccine-naive adults ages 55-74.</description>
          </group>
          <group group_id="O2">
            <title>Group IIA/B: Previous PPSV23, Single Injection</title>
            <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to adults ages 55-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Group IIAA/BB: Previous PPSV23, Two Injections</title>
            <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to adults ages 55-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Local and Systemic Adverse Events</title>
          <description>Participants maintained a memory aid to record daily the occurrence of local injection site reactions and systemic reactions for 8 days after vaccination based on their interference with daily activities for subjective symptoms or quantitative measurement of the reaction. All participants reporting events of any severity (mild, moderate, or severe) are counted. For measured reactions, participants are included if the reaction is &gt;0mm.</description>
          <population>All participants who received vaccination are included. Data were analyzed regardless of age strata as pre-specified in the study protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="180"/>
                    <measurement group_id="O3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (measurement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated oral temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feverishness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Unsolicited Vaccine-related Adverse Events.</title>
        <description>Association with PCV13 was determined by the investigator and defined as &quot;Related&quot;, meaning there was a known temporal relationship, or the event was known to occur in association with study product or with a product in a similar class of study products and no alternate etiology was identified.</description>
        <time_frame>Up to Day 28 post vaccination</time_frame>
        <population>All participants who received vaccination are included. Data were analyzed regardless of age strata as pre-specified in the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group IA/B: Pneumococcal Vaccine-naive, Single Injection</title>
            <description>Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to vaccine-naive adults ages 55-74.</description>
          </group>
          <group group_id="O2">
            <title>Group IIA/B: Previous PPSV23, Single Injection</title>
            <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to adults ages 55-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Group IIAA/BB: Previous PPSV23, Two Injections</title>
            <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to adults ages 55-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Unsolicited Vaccine-related Adverse Events.</title>
          <description>Association with PCV13 was determined by the investigator and defined as &quot;Related&quot;, meaning there was a known temporal relationship, or the event was known to occur in association with study product or with a product in a similar class of study products and no alternate etiology was identified.</description>
          <population>All participants who received vaccination are included. Data were analyzed regardless of age strata as pre-specified in the study protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Vaccine-related Serious Adverse Events.</title>
        <description>Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation thereof; was a congenital anomaly/birth defect; or may have jeopardized the participant, or required intervention to prevent one of the outcomes. Association with PCV13 was determined by the investigator and defined as &quot;Related&quot;, meaning there was a known temporal relationship, or the event was known to occur in association with study product or with a product in a similar class of study products and no alternate etiology was identified.</description>
        <time_frame>Up to Day 180 post vaccination</time_frame>
        <population>All participants who received vaccination are included. Data were analyzed regardless of age strata as pre-specified in the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group IA/B: Pneumococcal Vaccine-naive, Single Injection</title>
            <description>Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to vaccine-naive adults ages 55-74.</description>
          </group>
          <group group_id="O2">
            <title>Group IIA/B: Previous PPSV23, Single Injection</title>
            <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to adults ages 55-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Group IIAA/BB: Previous PPSV23, Two Injections</title>
            <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to adults ages 55-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Vaccine-related Serious Adverse Events.</title>
          <description>Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required inpatient hospitalization or prolongation thereof; was a congenital anomaly/birth defect; or may have jeopardized the participant, or required intervention to prevent one of the outcomes. Association with PCV13 was determined by the investigator and defined as &quot;Related&quot;, meaning there was a known temporal relationship, or the event was known to occur in association with study product or with a product in a similar class of study products and no alternate etiology was identified.</description>
          <population>All participants who received vaccination are included. Data were analyzed regardless of age strata as pre-specified in the study protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of Serotype-specific Opsonophagocytic Antibody (OPA) to 12 Vaccine Serotypes at Days 0 and 28 Post Vaccination.</title>
        <description>Blood was collected from all participants at Day 0 and Day 28 after receipt of vaccination. The geometric mean for each group was then assessed by serotype-specific opsonophagocytic antibody (OPA).</description>
        <time_frame>Day 0 and Day 28 post vaccination</time_frame>
        <population>All participants who received vaccination and had immunology samples obtained within the protocol-defined windows for Days 0, 28, and 180 are included. Three additional subjects were excluded for not meeting eligibility criteria or receipt of a non-study vaccine. Data were analyzed regardless of age strata as pre-specified in the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group IA/B: Pneumococcal Vaccine-naive, Single Injection</title>
            <description>Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to vaccine-naive adults ages 55-74.</description>
          </group>
          <group group_id="O2">
            <title>Group IIA/B: Previous PPSV23, Single Injection</title>
            <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to adults ages 55-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Group IIAA/BB: Previous PPSV23, Two Injections</title>
            <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to adults ages 55-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Serotype-specific Opsonophagocytic Antibody (OPA) to 12 Vaccine Serotypes at Days 0 and 28 Post Vaccination.</title>
          <description>Blood was collected from all participants at Day 0 and Day 28 after receipt of vaccination. The geometric mean for each group was then assessed by serotype-specific opsonophagocytic antibody (OPA).</description>
          <population>All participants who received vaccination and had immunology samples obtained within the protocol-defined windows for Days 0, 28, and 180 are included. Three additional subjects were excluded for not meeting eligibility criteria or receipt of a non-study vaccine. Data were analyzed regardless of age strata as pre-specified in the study protocol.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="6.0" upper_limit="7.7"/>
                    <measurement group_id="O2" value="20.9" lower_limit="16.9" upper_limit="25.7"/>
                    <measurement group_id="O3" value="20.4" lower_limit="16.9" upper_limit="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.0" lower_limit="177.5" upper_limit="262.7"/>
                    <measurement group_id="O2" value="75.2" lower_limit="61.4" upper_limit="92.1"/>
                    <measurement group_id="O3" value="95.1" lower_limit="78.6" upper_limit="115.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" lower_limit="16.6" upper_limit="25.5"/>
                    <measurement group_id="O2" value="92.3" lower_limit="72.2" upper_limit="117.9"/>
                    <measurement group_id="O3" value="81.3" lower_limit="63.7" upper_limit="103.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1808.9" lower_limit="1570.4" upper_limit="2083.5"/>
                    <measurement group_id="O2" value="926.6" lower_limit="787.5" upper_limit="1090.3"/>
                    <measurement group_id="O3" value="1451.3" lower_limit="1277.3" upper_limit="1649.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="7.6" upper_limit="10.2"/>
                    <measurement group_id="O2" value="53.0" lower_limit="41.7" upper_limit="67.4"/>
                    <measurement group_id="O3" value="36.8" lower_limit="29.3" upper_limit="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509.8" lower_limit="416.4" upper_limit="624.2"/>
                    <measurement group_id="O2" value="287.8" lower_limit="237.1" upper_limit="349.4"/>
                    <measurement group_id="O3" value="302.8" lower_limit="249.5" upper_limit="367.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="19.0" upper_limit="30.5"/>
                    <measurement group_id="O2" value="47.5" lower_limit="35.9" upper_limit="62.8"/>
                    <measurement group_id="O3" value="53.8" lower_limit="41.1" upper_limit="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3222.1" lower_limit="2697.1" upper_limit="3849.5"/>
                    <measurement group_id="O2" value="2256.7" lower_limit="1867.1" upper_limit="2727.6"/>
                    <measurement group_id="O3" value="2903.1" lower_limit="2364.5" upper_limit="3564.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" lower_limit="37.9" upper_limit="62.7"/>
                    <measurement group_id="O2" value="106.5" lower_limit="80.9" upper_limit="140.2"/>
                    <measurement group_id="O3" value="145.4" lower_limit="111.1" upper_limit="190.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2950.8" lower_limit="2453.0" upper_limit="3549.6"/>
                    <measurement group_id="O2" value="1767.8" lower_limit="1421.2" upper_limit="2199.0"/>
                    <measurement group_id="O3" value="2562.7" lower_limit="2095.5" upper_limit="3134.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" lower_limit="57.1" upper_limit="97.4"/>
                    <measurement group_id="O2" value="284.2" lower_limit="225.0" upper_limit="359.0"/>
                    <measurement group_id="O3" value="313.4" lower_limit="250.1" upper_limit="392.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4670.1" lower_limit="4064.9" upper_limit="5365.3"/>
                    <measurement group_id="O2" value="1692.4" lower_limit="1445.1" upper_limit="1982.0"/>
                    <measurement group_id="O3" value="2144.2" lower_limit="1870.2" upper_limit="2458.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1" lower_limit="71.7" upper_limit="115.8"/>
                    <measurement group_id="O2" value="210.8" lower_limit="164.5" upper_limit="270.2"/>
                    <measurement group_id="O3" value="246.6" lower_limit="193.3" upper_limit="314.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2337.5" lower_limit="2004.9" upper_limit="2725.3"/>
                    <measurement group_id="O2" value="1067.5" lower_limit="895.8" upper_limit="1272.2"/>
                    <measurement group_id="O3" value="1824.9" lower_limit="1566.0" upper_limit="2126.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.8" lower_limit="94.1" upper_limit="155.0"/>
                    <measurement group_id="O2" value="370.5" lower_limit="288.4" upper_limit="476.0"/>
                    <measurement group_id="O3" value="452.1" lower_limit="358.6" upper_limit="570.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1667.3" lower_limit="1400.6" upper_limit="1984.8"/>
                    <measurement group_id="O2" value="1102.2" lower_limit="916.4" upper_limit="1325.7"/>
                    <measurement group_id="O3" value="1342.5" lower_limit="1149.1" upper_limit="1568.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" lower_limit="33.4" upper_limit="51.1"/>
                    <measurement group_id="O2" value="206.5" lower_limit="164.0" upper_limit="260.0"/>
                    <measurement group_id="O3" value="200.8" lower_limit="157.2" upper_limit="256.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2133.1" lower_limit="1801.8" upper_limit="2525.3"/>
                    <measurement group_id="O2" value="948.3" lower_limit="796.1" upper_limit="1129.6"/>
                    <measurement group_id="O3" value="1373.2" lower_limit="1181.6" upper_limit="1596.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.2" lower_limit="131.4" upper_limit="193.0"/>
                    <measurement group_id="O2" value="540.4" lower_limit="446.4" upper_limit="654.1"/>
                    <measurement group_id="O3" value="499.8" lower_limit="407.9" upper_limit="612.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2981.9" lower_limit="2610.4" upper_limit="3406.3"/>
                    <measurement group_id="O2" value="1828.8" lower_limit="1608.6" upper_limit="2079.1"/>
                    <measurement group_id="O3" value="2316.3" lower_limit="2046.2" upper_limit="2622.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" lower_limit="52.6" upper_limit="80.0"/>
                    <measurement group_id="O2" value="153.4" lower_limit="123.7" upper_limit="190.2"/>
                    <measurement group_id="O3" value="169.4" lower_limit="138.8" upper_limit="206.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1415.5" lower_limit="1237.2" upper_limit="1619.6"/>
                    <measurement group_id="O2" value="727.6" lower_limit="622.2" upper_limit="850.9"/>
                    <measurement group_id="O3" value="1050.7" lower_limit="912.1" upper_limit="1210.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="14.1" upper_limit="22.3"/>
                    <measurement group_id="O2" value="52.6" lower_limit="40.7" upper_limit="68.0"/>
                    <measurement group_id="O3" value="50.6" lower_limit="39.3" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F, Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="947.4" lower_limit="762.2" upper_limit="1177.4"/>
                    <measurement group_id="O2" value="652.7" lower_limit="515.2" upper_limit="827.0"/>
                    <measurement group_id="O3" value="834.4" lower_limit="674.5" upper_limit="1032.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity: Serotype-specific OPA Titer to 12 Vaccine Serotypes at Days 0 and 180 Post Vaccination.</title>
        <description>Blood was collected from all participants at Days 0 and 180 after receipt of vaccination. The geometric mean for each group was then assessed by serotype-specific opsonophagocytic antibody (OPA).</description>
        <time_frame>Day 0 and Day 180 post vaccination</time_frame>
        <population>All participants who received vaccination and had immunology samples obtained within the protocol-defined windows for Days 0, 28, and 180 are included. Three additional subjects were excluded for not meeting eligibility criteria or receipt of a non-study vaccine. Data were analyzed regardless of age strata as pre-specified in the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group IA/B: Pneumococcal Vaccine-naive, Single Injection</title>
            <description>Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to vaccine-naive adults ages 55-74.</description>
          </group>
          <group group_id="O2">
            <title>Group IIA/B: Previous PPSV23, Single Injection</title>
            <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to adults ages 55-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
          </group>
          <group group_id="O3">
            <title>Group IIAA/BB: Previous PPSV23, Two Injections</title>
            <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to adults ages 55-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity: Serotype-specific OPA Titer to 12 Vaccine Serotypes at Days 0 and 180 Post Vaccination.</title>
          <description>Blood was collected from all participants at Days 0 and 180 after receipt of vaccination. The geometric mean for each group was then assessed by serotype-specific opsonophagocytic antibody (OPA).</description>
          <population>All participants who received vaccination and had immunology samples obtained within the protocol-defined windows for Days 0, 28, and 180 are included. Three additional subjects were excluded for not meeting eligibility criteria or receipt of a non-study vaccine. Data were analyzed regardless of age strata as pre-specified in the study protocol.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="6.0" upper_limit="7.7"/>
                    <measurement group_id="O2" value="20.9" lower_limit="16.9" upper_limit="25.7"/>
                    <measurement group_id="O3" value="20.4" lower_limit="16.9" upper_limit="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1, Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" lower_limit="76.4" upper_limit="141.1"/>
                    <measurement group_id="O2" value="45.4" lower_limit="36.9" upper_limit="55.9"/>
                    <measurement group_id="O3" value="54.4" lower_limit="45.1" upper_limit="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" lower_limit="16.6" upper_limit="25.5"/>
                    <measurement group_id="O2" value="92.3" lower_limit="72.2" upper_limit="117.9"/>
                    <measurement group_id="O3" value="81.3" lower_limit="63.7" upper_limit="103.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4, Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="718.3" lower_limit="619.4" upper_limit="833.1"/>
                    <measurement group_id="O2" value="483.9" lower_limit="407.4" upper_limit="574.6"/>
                    <measurement group_id="O3" value="734.9" lower_limit="641.8" upper_limit="841.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="7.6" upper_limit="10.2"/>
                    <measurement group_id="O2" value="53.0" lower_limit="41.7" upper_limit="67.4"/>
                    <measurement group_id="O3" value="36.8" lower_limit="29.3" upper_limit="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5, Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.6" lower_limit="190.7" upper_limit="288.6"/>
                    <measurement group_id="O2" value="185.4" lower_limit="151.6" upper_limit="226.8"/>
                    <measurement group_id="O3" value="167.6" lower_limit="136.4" upper_limit="205.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="19.0" upper_limit="30.5"/>
                    <measurement group_id="O2" value="47.5" lower_limit="35.9" upper_limit="62.8"/>
                    <measurement group_id="O3" value="53.8" lower_limit="41.1" upper_limit="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A, Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1568.5" lower_limit="1321.6" upper_limit="1861.6"/>
                    <measurement group_id="O2" value="1155.8" lower_limit="962.2" upper_limit="1388.4"/>
                    <measurement group_id="O3" value="1384.4" lower_limit="1132.5" upper_limit="1692.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" lower_limit="37.9" upper_limit="62.7"/>
                    <measurement group_id="O2" value="106.5" lower_limit="80.9" upper_limit="140.2"/>
                    <measurement group_id="O3" value="145.4" lower_limit="111.1" upper_limit="190.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B, Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1425.1" lower_limit="1188.9" upper_limit="1708.2"/>
                    <measurement group_id="O2" value="996.1" lower_limit="806.8" upper_limit="1229.9"/>
                    <measurement group_id="O3" value="1335.8" lower_limit="1084.0" upper_limit="1646.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" lower_limit="57.1" upper_limit="97.4"/>
                    <measurement group_id="O2" value="284.2" lower_limit="225.0" upper_limit="359.0"/>
                    <measurement group_id="O3" value="313.4" lower_limit="250.1" upper_limit="392.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F, Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2329.0" lower_limit="2053.3" upper_limit="2641.8"/>
                    <measurement group_id="O2" value="1063.3" lower_limit="913.6" upper_limit="1237.6"/>
                    <measurement group_id="O3" value="1386.9" lower_limit="1224.5" upper_limit="1570.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1" lower_limit="71.7" upper_limit="115.8"/>
                    <measurement group_id="O2" value="210.8" lower_limit="164.5" upper_limit="270.2"/>
                    <measurement group_id="O3" value="246.6" lower_limit="193.3" upper_limit="314.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V, Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1191.7" lower_limit="1016.9" upper_limit="1396.5"/>
                    <measurement group_id="O2" value="722.4" lower_limit="602.3" upper_limit="866.5"/>
                    <measurement group_id="O3" value="1142.8" lower_limit="979.2" upper_limit="1333.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.8" lower_limit="94.1" upper_limit="155.0"/>
                    <measurement group_id="O2" value="370.5" lower_limit="288.4" upper_limit="476.0"/>
                    <measurement group_id="O3" value="452.1" lower_limit="358.6" upper_limit="570.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14, Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="992.3" lower_limit="844.3" upper_limit="1166.1"/>
                    <measurement group_id="O2" value="838.3" lower_limit="692.2" upper_limit="1015.3"/>
                    <measurement group_id="O3" value="1056.5" lower_limit="908.3" upper_limit="1229.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" lower_limit="33.4" upper_limit="51.1"/>
                    <measurement group_id="O2" value="206.5" lower_limit="164.0" upper_limit="260.0"/>
                    <measurement group_id="O3" value="200.8" lower_limit="157.2" upper_limit="256.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C, Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="964.7" lower_limit="806.2" upper_limit="1154.5"/>
                    <measurement group_id="O2" value="590.9" lower_limit="490.7" upper_limit="711.5"/>
                    <measurement group_id="O3" value="778.4" lower_limit="655.0" upper_limit="925.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.2" lower_limit="131.4" upper_limit="193.0"/>
                    <measurement group_id="O2" value="540.4" lower_limit="446.4" upper_limit="654.1"/>
                    <measurement group_id="O3" value="499.8" lower_limit="407.9" upper_limit="612.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A, Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1522.3" lower_limit="1340.3" upper_limit="1728.9"/>
                    <measurement group_id="O2" value="1272.1" lower_limit="1120.7" upper_limit="1444.1"/>
                    <measurement group_id="O3" value="1508.3" lower_limit="1326.3" upper_limit="1715.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" lower_limit="52.6" upper_limit="80.0"/>
                    <measurement group_id="O2" value="153.4" lower_limit="123.7" upper_limit="190.2"/>
                    <measurement group_id="O3" value="169.4" lower_limit="138.8" upper_limit="206.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F, Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="702.3" lower_limit="612.2" upper_limit="805.5"/>
                    <measurement group_id="O2" value="481.4" lower_limit="412.3" upper_limit="562.0"/>
                    <measurement group_id="O3" value="607.1" lower_limit="524.9" upper_limit="702.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="14.1" upper_limit="22.3"/>
                    <measurement group_id="O2" value="52.6" lower_limit="40.7" upper_limit="68.0"/>
                    <measurement group_id="O3" value="50.6" lower_limit="39.3" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F, Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490.7" lower_limit="394.1" upper_limit="611.0"/>
                    <measurement group_id="O2" value="353.7" lower_limit="277.2" upper_limit="451.4"/>
                    <measurement group_id="O3" value="435.7" lower_limit="349.2" upper_limit="543.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited events were collected for 8 days after vaccination, unsolicited AEs through 28 days after vaccination, and SAEs through 180 days after vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IA: Pneumococcal Vaccine-naive, Age 55-64, Single Injection</title>
          <description>Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to vaccine-naive adults ages 55-64.</description>
        </group>
        <group group_id="E2">
          <title>IB: Pneumococcal Vaccine-naive, Age 65-74, Single Injection</title>
          <description>Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to vaccine-naive adults ages 65-74.</description>
        </group>
        <group group_id="E3">
          <title>IIA: Previous PPSV23, Age 55-64, Single Injection</title>
          <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to adults ages 55-64 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
        </group>
        <group group_id="E4">
          <title>IIB: Previous PPSV23, Age 65-74, Single Injection</title>
          <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection to adults ages 65-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
        </group>
        <group group_id="E5">
          <title>IIAA: Previous PPSV23, Age 55-64, Two Injections</title>
          <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to adults ages 55-64 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
        </group>
        <group group_id="E6">
          <title>IIBB: Previous PPSV23, Age 65-74, Two Injections</title>
          <description>Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to adults ages 65-74 with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the vulva</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="115" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="126" subjects_at_risk="140"/>
                <counts group_id="E6" subjects_affected="131" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="139"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="140"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vaccination site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <description>Solicited on the memory aid as &quot;Feverishness&quot;</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="139"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E5" events="16" subjects_affected="16" subjects_at_risk="140"/>
                <counts group_id="E6" events="13" subjects_affected="13" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Solicited on the memory aid as &quot;Fatigue/Malaise (decreased energy)&quot;</description>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="164"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="147"/>
                <counts group_id="E3" events="30" subjects_affected="30" subjects_at_risk="139"/>
                <counts group_id="E4" events="26" subjects_affected="26" subjects_at_risk="145"/>
                <counts group_id="E5" events="43" subjects_affected="43" subjects_at_risk="140"/>
                <counts group_id="E6" events="43" subjects_affected="43" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="140"/>
                <counts group_id="E6" events="13" subjects_affected="13" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <description>Solicited on the memory aid as &quot;Pain&quot;</description>
                <counts group_id="E1" events="87" subjects_affected="87" subjects_at_risk="164"/>
                <counts group_id="E2" events="61" subjects_affected="61" subjects_at_risk="147"/>
                <counts group_id="E3" events="86" subjects_affected="86" subjects_at_risk="139"/>
                <counts group_id="E4" events="67" subjects_affected="67" subjects_at_risk="145"/>
                <counts group_id="E5" events="94" subjects_affected="94" subjects_at_risk="140"/>
                <counts group_id="E6" events="93" subjects_affected="93" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <description>Solicited on the memory aid as &quot;Tenderness&quot;</description>
                <counts group_id="E1" events="120" subjects_affected="120" subjects_at_risk="164"/>
                <counts group_id="E2" events="93" subjects_affected="93" subjects_at_risk="147"/>
                <counts group_id="E3" events="88" subjects_affected="88" subjects_at_risk="139"/>
                <counts group_id="E4" events="92" subjects_affected="92" subjects_at_risk="145"/>
                <counts group_id="E5" events="109" subjects_affected="109" subjects_at_risk="140"/>
                <counts group_id="E6" events="105" subjects_affected="105" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <description>Solicited on the memory aid as &quot;Redness/erythema measurement&quot;, reported as experienced if size &gt;0mm</description>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="164"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="147"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="139"/>
                <counts group_id="E4" events="25" subjects_affected="25" subjects_at_risk="145"/>
                <counts group_id="E5" events="31" subjects_affected="31" subjects_at_risk="140"/>
                <counts group_id="E6" events="22" subjects_affected="22" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <description>Solicited on the memory aid as &quot;Swelling/induration&quot;</description>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="164"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="147"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="139"/>
                <counts group_id="E4" events="25" subjects_affected="25" subjects_at_risk="145"/>
                <counts group_id="E5" events="24" subjects_affected="24" subjects_at_risk="140"/>
                <counts group_id="E6" events="21" subjects_affected="21" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <description>Solicited on the memory aid as &quot;Swelling/induration measurement&quot;, reported as experienced in size &gt;0mm</description>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="164"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="147"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="139"/>
                <counts group_id="E4" events="24" subjects_affected="24" subjects_at_risk="145"/>
                <counts group_id="E5" events="23" subjects_affected="23" subjects_at_risk="140"/>
                <counts group_id="E6" events="22" subjects_affected="22" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="164"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="145"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E6" events="18" subjects_affected="18" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Solicited on the memory aid as &quot;New muscle pain (exclusive of the injection site)&quot;</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="164"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="147"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="139"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="145"/>
                <counts group_id="E5" events="18" subjects_affected="18" subjects_at_risk="140"/>
                <counts group_id="E6" events="18" subjects_affected="18" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Solicited on the memory aid as &quot;Aggravated muscle pain (increase in existing pain, exclusive of the injection site)&quot;</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E5" events="17" subjects_affected="17" subjects_at_risk="140"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Solicited on the memory aid as &quot;New joint pain (arthralgia)&quot;</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="139"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="145"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="140"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Solicited on the memory aid as &quot;Aggravated joint pain (increase in existing pain)&quot;</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="145"/>
                <counts group_id="E5" events="16" subjects_affected="16" subjects_at_risk="140"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="164"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="147"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="139"/>
                <counts group_id="E4" events="18" subjects_affected="18" subjects_at_risk="145"/>
                <counts group_id="E5" events="36" subjects_affected="36" subjects_at_risk="140"/>
                <counts group_id="E6" events="27" subjects_affected="27" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa A. Jackson, MD, MPH</name_or_title>
      <organization>Group Health Research Institute</organization>
      <phone>206-442-5216</phone>
      <email>Jackson.L@ghc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

